September 7, 2016Open Access

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation

Key Points

Key points are not available for this paper at this time.

Abstract

Somatic mutation in ASXL1, RUNX1, or TP53 is independently associated with unfavorable outcomes and shorter survival after allogeneic HSCT for patients with MDS and MDS/AML. Accounting for these genetic lesions may improve the prognostication precision in clinical practice and in designing clinical trials.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Porta et al. (Wed,) studied this question.

synapsesocial.com/papers/69d80a6bfc5937d393ae2bcb https://doi.org/https://doi.org/10.1200/jco.2016.67.3616

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R2014 · 177 citations
2Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes2014 · 148 citations
3Frequent pathway mutations of splicing machinery in myelodysplasia2011 · 2,060 citations
4The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes2009 · 4,416 citations
5Biomarker: Predictive or Prognostic?2015 · 492 citations

AI에게 질문

Bookmark

View Full Paper